BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 20846830)

  • 1. In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB; Saravolatz LD; Husain N
    Int J Antimicrob Agents; 2010 Nov; 36(5):478-80. PubMed ID: 20846830
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.
    Denis O; Deplano A; Nonhoff C; Hallin M; De Ryck R; Vanhoof R; De Mendonça R; Struelens MJ
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2680-5. PubMed ID: 16870758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
    J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.
    Saravolatz LD; Pawlak J; Johnson LB
    Clin Infect Dis; 2012 Aug; 55(4):582-6. PubMed ID: 22615331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus strains with reduced susceptibility to daptomycin, linezolid or vancomycin, and strains with defined SCCmec types.
    Farrell DJ; Flamm RK; Sader HS; Jones RN
    Int J Antimicrob Agents; 2014 Apr; 43(4):323-7. PubMed ID: 24411474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
    Appleman MD; Citron DM
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro bactericidal activity of ceftobiprole against hospital- and community-associated methicillin-resistant Staphylococcus aureus.
    Borbone S; Campanile F; Bongiorno D; Stefani S
    J Antimicrob Chemother; 2010 Mar; 65(3):591-4. PubMed ID: 20083552
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus using an in vitro model.
    Zhanel GG; Rossnagel E; Nichol K; Cox L; Karlowsky JA; Zelenitsky S; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2011 Jun; 66(6):1301-5. PubMed ID: 21429940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital.
    Hsueh PR; Lee SY; Perng CL; Chang TY; Lu JJ
    Int J Antimicrob Agents; 2010 Oct; 36(4):307-12. PubMed ID: 20685086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular activity of the peptide antibiotic NZ2114: studies with Staphylococcus aureus and human THP-1 monocytes, and comparison with daptomycin and vancomycin.
    Brinch KS; Tulkens PM; Van Bambeke F; Frimodt-Møller N; Høiby N; Kristensen HH
    J Antimicrob Chemother; 2010 Aug; 65(8):1720-4. PubMed ID: 20534628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
    Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
    Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and molecular characteristics of community-associated methicillin-resistant and methicillin-susceptible Staphylococcus aureus from skin/soft tissue infections in a children's hospital in Beijing, China.
    Wu D; Wang Q; Yang Y; Geng W; Wang Q; Yu S; Yao K; Yuan L; Shen X
    Diagn Microbiol Infect Dis; 2010 May; 67(1):1-8. PubMed ID: 20227225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin.
    Entenza JM; Giddey M; Vouillamoz J; Moreillon P
    Int J Antimicrob Agents; 2010 May; 35(5):451-6. PubMed ID: 20185277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.